Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases

Cancer

Volumn 92, Issue 9, 2001, Pages 2297-2308

  Coffey, Ronan N T ^a   Watson, R William G ^a   Hegarty, Paul K ^a   Watson, Chanel L ^a   Wolohan, Linda ^a   Brady, Hugh R ^a   O'Keane, Conor ^a   Fitzpatrick, John M ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Apoptosis; Bcl 2, glutathione; Caspases; Prostate carcinoma

Indexed keywords

CASPASE; CASPASE 3; CASPASE 8; CYCLOHEXIMIDE; ETOPOSIDE; FAS ANTIBODY; GLUTATHIONE; MALEIC ACID DIETHYL ESTER;

APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CHEMOSENSITIVITY; ENZYME ACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RADIATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA; CASPASES; ETOPOSIDE; GENES, BCL-2; GLUTATHIONE; HUMANS; IMMUNOTHERAPY; INTRACELLULAR FLUID; MALE; MALEATES; PROSTATIC NEOPLASMS; RADIOTHERAPY; SULFHYDRYL COMPOUNDS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0035498497     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20011101)92:9<2297::AID-CNCR1576>3.0.CO;2-B     Document Type: Article

References (56)

1. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer
2. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line
3. The cellular and molecular basis of prostate cancer
4. Basic science aspects of prostate cancer
5. Modulating apoptosis: Current applications and prospects for future drug development
6. Apoptosis regulating genes in prostate cancer
7. Proteolytic activities that mediate apoptosis
8. Proteases, proteolysis, and apoptosis
9. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (caspase-3), a cell death protease
10. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
11. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells
12. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma
13. Inhibition of caspases by cytokine response modifier A blocks androgen ablation- mediated prostate cancer cell death in vivo
14. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
15. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
16. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers
17. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
18. Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer
19. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle
20. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
21. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormonerefractory human prostate cancer
22. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells
23. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity
24. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis
25. Resistance to radiation induced apoptosis in bcl-2-expressing cells is reversed by depleting cellular thiols
26. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis
27. Enhancement of radiation response of prostatic carcinoma by lonidamine
28. Improved therapeutic response by distinct timing of multiple heat treatments during interstitial radiation in the Dunning R3327 prostate tumor model
29. Thiol mediated apoptosis in prostate cancer cells
30. Serial culture of single adult human prostatic epithelia cells in serum free medium containing low calcium and a new growth factor from bovine brain
31. Bcl-2 over-expression delays radiation -induced apoptosis without affecting the clonogenic survival of human prostate cancer cells
32. Alteration of caspase-3 (CPP32/Yama/apopain) in wild type MCF-7, breast cancer cells
33. Bcl-2 expression causes redistribution of glutathione to the nucleus
34. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl) all-trans retinamide
35. Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line
36. Camptothecin sensitizes androgen-independent prostate cancer cells to anti-Fas-induced apoptosis
37. Radiosensitizing effect of cisplatin in prostate cancer cell lines
38. Radiosensitization mediated by a transfected anti-erbB-2 single-chain antibody in vitro and in vivo
39. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis
40. Interstitial radiation and hyperthermia in the Dunning R3327 prostate tumour model: Therapeutic efficacy depends on radiation dose-rate, sequence and frequency of heating
41. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation
42. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: Experimental and clinical results
43. Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer
44. Activation of caspases by death receptors
45. Apoptosis by death factor
46. Fas-mediated apoptosis in human prostatic carcinoma cell lines
47. Immunological approaches for the treatment of prostate cancer
48. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
49. Gene transfer of Fas ligand induces tumour regression in vivo
50. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage
51. Apoptosis in prostate cancer. Molecular basis to study hormone refractory mechanisms
52. Molecular biology of prostate cancer
53. Molecular genetics of prostate cancer
54. Modulation of antioxidant defenses during apoptosis
55. Redox regulation of apoptotic cell death
56. Current challenges of gene therapy for prostate cancer